Longitudinal analysis of patterns and predictors of changes in self-reported adherence to antiretroviral therapy: Swiss HIV cohort study

Journal of Acquired Immune Deficiency Syndromes

Volumn 54, Issue 2, 2010, Pages 197-203

  Glass, Tracy R ^a   Battegay, Manuel ^b   Cavassini, Matthias ^c   De Geest, Sabina ^d   Furrer, Hansjakob ^e   Vernazza, Pietro L ^f   Hirschel, Bernard ^g   Bernasconi, Enos ^h   Rickenbach, Martin ^c   Günthard, Huldrych F ⁱ   Bucher, Heiner C ^a,b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d UNIVERSITY OF BASEL   (Switzerland)

^e UNIVERSITY OF BERN   (Switzerland)

^f Infectious Diseases   (Switzerland)

^g GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^h REGIONAL HOSPITAL OF LUGANO   (Switzerland)

ⁱ UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Antiretroviral therapy; Cohort study; Latent trajectory analysis; Medication adherence; Patterns; Repeated measures

Indexed keywords

ANTIRETROVIRUS AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BEHAVIOR; COHORT ANALYSIS; CONTROLLED STUDY; DEPRESSION; EDUCATION; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; LIFE EVENT; LIPODYSTROPHY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUESTIONNAIRE; SELF REPORT; SWITZERLAND;

ADULT; AGE FACTORS; ANTI-HIV AGENTS; EDUCATIONAL STATUS; FEMALE; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; MALE; MEDICATION ADHERENCE; MIDDLE AGED; QUESTIONNAIRES; RISK FACTORS; SEX FACTORS; SWITZERLAND;

EID: 77953040583     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181ca48bf     Document Type: Article

References (29)

1. Egger M, Hirschel B, Francioli P, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. BMJ. 1997;315: 1194-1199.
2. Hogg RS, O'Shaughnessy MV, Gataric N, et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet. 1997;349:1294.
3. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003; 362:22-29.
4. Lai D, Hardy RJ. An update on the impact of HIV/AIDS on life expectancy in the United States. AIDS. 2004;18:1732-1734.
5. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet. 1999;353: 863-868. (Pubitemid 29126872)
6. Paredes R, Mocroft A, Kirk O, et al. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Arch Intern Med. 2000;160:1123-1132.
7. Glass TR, De GS, Hirschel B, et al. Self-reported non-adherence to antiretroviral therapy repeatedly assessed by two questions predicts treatment failure in virologically suppressed patients. Antivir Ther. 2008; 13:77-85.
8. Gross R, Yip B, Re VL III, et al. A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. J Infect Dis. 2006;194:1108-1114.
9. Lima VD, Harrigan R, Murray M, et al. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals. AIDS. 2008;22:2371-2380.
10. Tam LW, Chui CK, Brumme CJ, et al. The relationship between resistance and adherence in drug-naive individuals initiating HAART is specific to individual drug classes. J Acquir Immune Defic Syndr. 2008;49:266-271.
11. Bangsberg DR, Acosta EP, Gupta R, et al. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS. 2006;20:223-231.
12. Glass TR, De Geest S, Weber R, et al. Correlates of self-reported nonadherence to antiretroviral therapy in HIV-infected patients: the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr. 2006;41:385-392.
13. Ammassari A, Trotta MP, Murri R, et al. Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J Acquir Immune Defic Syndr. 2002;31(Suppl 3):S123-S127.
14. Gebo KA, Keruly J, Moore RD. Association of social stress, illicit drug use, and health beliefs with nonadherence to antiretroviral therapy. J Gen Intern Med. 2003;18:104-111.
15. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005; 353:487-497.
16. Lazo M, Gange SJ, Wilson TE, et al. Patterns and predictors of changes in adherence to highly active antiretroviral therapy: longitudinal study of men and women. Clin Infect Dis. 2007;45:1377-1385.
17. Levine AJ, Hinkin CH, Castellon SA, et al. Variations in patterns of highly active antiretroviral therapy (HAART) adherence. AIDS Behav. 2005;9: 355-362.
18. Kleeberger CA, Buechner J, Palella F, et al. Changes in adherence to highly active antiretroviral therapy medications in the Multicenter AIDS Cohort Study. AIDS. 2004;18:683-688.
19. Mannheimer S, Friedland G, Matts J, et al. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis. 2002; 34:1115-1121.
20. Carrieri P, Cailleton V, Le Moing V, et al. The dynamic of adherence to highly active antiretroviral therapy: results from the French National APROCO cohort. J Acquir Immune Defic Syndr. 2001;28:232-239.
21. World Health Organization. Adherence to Long-Term Therapies: Evidence for Action. World Health Organization; 2004. Available at: http://www.who.int/ chronic-conditions/adherencereport/en/.
22. International Guide for Monitoring Alcohol Consumptionand Related Harm. Geneva, Switzerland: World Health Organization; 2009. Available at: http://whqlibdoc.who.int/hq/2000/WHO-MSD-MSB-00.4.pdf. Accessed August 1, 2009.
23. Conen A, Fehr J, Glass TR, et al. Self-reported alcohol consumption and its association with adherence and outcome of antiretroviral therapy in the Swiss HIV Cohort Study. Antivir Ther. 2009;14:349-357.
24. Jones BL, Nagin DS. Advances in Group-Based Trajectory Modeling and a SAS Procedure for Estimating Them. Sociol Methods Res. 2007;35: 542-571.
25. Hagenaars JA, McCutcheon AL, eds. Applied Latent Class Analysis. New York, NY: Cambridge University Press; 2002.
26. Arnsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med. 2002;17:377-381.
27. Wagner G, Miller LG. Is the influence of social desirability on patients' self-reported adherence overrated? J Acquir Immune Defic Syndr. 2004; 35:203-204.
28. Simoni JM, Kurth AE, Pearson CR, et al. Self-report measures of antiretroviral therapy adherence: A review with recommendations for HIV research and clinical management. AIDS Behav. 2006;10:227-245.
29. Nieuwkerk PT, Oort FJ. Self-reported adherence to antiretroviral therapy for HIV-1 infection and virologic treatment response: a meta-analysis. J Acquir Immune Defic Syndr. 2005;38:445-448.